Lead Product(s): SO-C101,Pembrolizumab
Therapeutic Area: Oncology Product Name: SO-C101
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Cytune Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
SOTIO will present three posters, including a late breaking poster on the clinical data from the ongoing Phase 1 study of IL-15 superagonist SO-C101 for the treatment of advanced solid tumors.